TriFlo Cardiovascular

About TriFlo Cardiovascular

Triflo Cardiovascular, Inc., based in Southern California and founded in 2017, specializes in developing advanced structural heart devices specifically designed to address tricuspid regurgitation (TR). TR is a condition where the tricuspid valve fails, causing blood to flow backward during heart contractions, which can lead to severe health issues, especially among the elderly. Triflo's core product is a patented transcatheter heart valve technology that has been developed from inception to clinical use within six years, despite challenges such as the Covid pandemic. The company serves the medical device market, particularly focusing on healthcare providers and patients requiring heart valve interventions. Triflo's business model revolves around the development, clinical validation, and commercialization of its heart valve technologies. Revenue is generated through the sale of these medical devices to healthcare institutions and through partnerships with other medical technology firms. The company is led by Luca Pesce, who has over 15 years of experience in the field and has previously led successful clinical testing of similar heart valve technologies.